Abstract

Non-clear renal cell carcinomas (nccRCCs) are less frequent in kidney cancer with histopathological heterogeneity. A better understanding of the tumor biology of nccRCC can provide more effective treatment paradigms for different subtypes. To reveal the heterogeneity of tumor microenvironment (TME) in nccRCC, we performed 10x sing-cell genomics on tumor and normal tissues from patients with papillary renal cell carcinoma (pRCC), chromophobe RCC (chrRCC), collecting duct carcinoma (CDRCC) and sarcomatoid RCC (sarRCC). 15 tissue samples were finally included. 34561 cells were identified as 16 major cell clusters with 34 cell subtypes. Our study presented the sing-cell landscape for four types of nccRCC, and demonstrated that CD8+ T cells exhaustion, tumor-associated macrophages (TAMs) and sarcomatoid process were the pivotal factors in immunosuppression of nccRCC tissues and were closely correlated with poor prognosis. Abnormal metabolic patterns were present in both cancer cells and tumor-infiltrating stromal cells, such as fibroblasts and endothelial cells. Combined with CIBERSORTx tool, the expression data of bulk RNA-seq from TCGA were labeled with cell types of our sing-cell data. Calculation of the relative abundance of cell types revealed that greater proportion of exhausted CD8+ T cells, TAMs and sarRCC derived cells were correlated with poor prognosis in the cohort of 274 nccRCC patients. To the best of our knowledge, this is the first study that provides a more comprehensive sight about the heterogeneity and tumor biology of nccRCC, which may potentially facilitate the development of more effective therapies for nccRCC.

Highlights

  • The new diagnosis of kidney cancer is estimated to reach 73,750 cases in 2020 [1]

  • Our study presented the sing-cell landscape for four types of non-clear cell RCC (nccRCC), and demonstrated that CD8+ T cells exhaustion, tumor-associated macrophages (TAMs) and sarcomatoid process were the pivotal factors in immunosuppression of nccRCC tissues and were closely correlated with poor prognosis

  • Several small direct comparative clinical studies currently available have shown that the targeted therapies for nccRCC are not significantly different [8, 9], but it is difficult to determine the optimal treatment or reach consensus due to the limited data concerning the efficacy of the present therapies on nccRCCs [7]

Read more

Summary

Introduction

The new diagnosis of kidney cancer is estimated to reach 73,750 cases in 2020 [1]. The proportion of renal cell carcinoma (RCC) in kidney cancer is up to 85% [2], of which clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC) account for 75% and 25%, respectively, approximately [3]. The hypoxia pathway published scRNA-seq study of kidney cancer, Young et al [15] was upregulated in all the nccRCC cells except CDRCC, which described the single-cell profile for ccRCC, pRCC, and Wilms tumor.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call